What is HC Wainwright’s Estimate for RMTI Q1 Earnings?

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Rockwell Medical in a research report issued to clients and investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.01) per share for the quarter. HC Wainwright has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.01 EPS, Q4 2027 earnings at $0.02 EPS and FY2027 earnings at $0.04 EPS.

Other equities research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $2.00.

Rockwell Medical Trading Down 2.3%

Shares of NASDAQ:RMTI opened at $0.85 on Tuesday. The company has a market cap of $33.50 million, a P/E ratio of -5.67 and a beta of 1.71. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.63. Rockwell Medical has a 1 year low of $0.78 and a 1 year high of $2.10. The stock’s fifty day moving average price is $1.01 and its 200-day moving average price is $1.04.

Rockwell Medical (NASDAQ:RMTI) last issued its earnings results on Thursday, March 26th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). The business had revenue of $18.35 million for the quarter, compared to analysts’ expectations of $18.58 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%.

Hedge Funds Weigh In On Rockwell Medical

A number of institutional investors and hedge funds have recently modified their holdings of RMTI. XTX Topco Ltd grew its holdings in shares of Rockwell Medical by 286.5% in the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after acquiring an additional 46,029 shares during the period. Jane Street Group LLC bought a new position in Rockwell Medical in the fourth quarter valued at about $84,000. Geode Capital Management LLC lifted its holdings in Rockwell Medical by 12.9% in the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after acquiring an additional 41,668 shares during the period. GSA Capital Partners LLP boosted its position in Rockwell Medical by 635.1% in the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock worth $197,000 after purchasing an additional 141,672 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Rockwell Medical by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock valued at $1,625,000 after purchasing an additional 148,737 shares during the period. 23.31% of the stock is currently owned by hedge funds and other institutional investors.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.